Vericel Corp
VCELHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 10:55 AM ET
58.31-0.72 (-1.22%)
2026-11-11 16:55 CET
Market cap
3,012.29 USD m
Revenue, TTM
324.17 USD m
Net income, TTM
33.31 USD m
Free cash flow, TTM
57.89 USD m
EPS diluted, TTM
0.63
P/E
92.29
Price
VCEL against its 20, 50 and 200-day averages2050200beat
2.4% under the 52-week high of 59.75 on 11 Nov 2026. 52-week low 28.95 on 27 Mar 2026. Last 15 sessions, 51.5% high to low
Profile
VCEL52-week range, 95% of the way up
28.9559.72
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
| Index | RUT |
|---|---|
| Employees | 398 |
| IPO | Feb 04, 1997 |
| Beta | 0.99 |
| ATR, 14d | 2.54 |
| Rel volume | 0.50 |
| Short float | 10.64% |
| Insider own | 1.19% |
| Inst own | 110.68% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | 2.98B |
| Enterprise Value | 2.90B |
| Income | 33.31M |
| Sales | 324.17M |
| Book/sh | 7.53 |
| Cash/sh | 3.34 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | 0.00% |
| Employees | 398 |
| IPO | Feb 04, 1997 |
Ratios
| P/E | 92.29 |
|---|---|
| Forward P/E | 61.70 |
| PEG | 0.97 |
| P/S | 9.18 |
| P/B | 7.75 |
| P/C | 17.48 |
| P/FCF | 51.40 |
| EV/EBITDA | 71.29 |
| EV/Sales | 8.94 |
| Quick Ratio | 4.82 |
| Current Ratio | 5.13 |
| Debt/Eq | 0.24 |
| LT Debt/Eq | 0.20 |
| Option/Short | Yes / Yes |
Earnings
| EPS (ttm) | 0.63 |
|---|---|
| EPS next Y | 0.94 |
| EPS next Q | 0.57 |
| EPS this Y | 137.11% |
| EPS next Y | 24.55% |
| EPS next 5Y | 63.33% |
| EPS past 3/5Y | - 39.20% |
| Sales past 3/5Y | 18.90% 17.34% |
| EPS Y/Y TTM | 147.62% |
| Sales Y/Y TTM | 25.30% |
| EPS Q/Q | 173.42% |
| Sales Q/Q | 26.47% |
| Earnings | Nov 05 BMO |
| EPS/Sales Surpr. | 371.20% 9.47% |
Ownership
| Insider Own | 1.19% |
|---|---|
| Insider Trans | -22.13% |
| Inst Own | 110.68% |
| Inst Trans | -1.39% |
| ROA | 6.86% |
| ROE | 9.44% |
| ROIC | 7.20% |
| Gross Margin | 74.47% |
| Oper. Margin | 8.32% |
| Profit Margin | 10.27% |
| SMA20 | 28.39% |
| SMA50 | 38.50% |
| SMA200 | 48.79% |
| Trades | - |
Technical
| Shs Outstand | 51.04M |
|---|---|
| Shs Float | 50.42M |
| Short Float | 10.64% |
| Short Ratio | 8.56 |
| Short Interest | 5.36M |
| 52W High | 59.72 -2.36% |
| 52W Low | 28.95 101.42% |
| Volatility | 8.14% 4.84% |
| ATR (14) | 2.54 |
| RSI (14) | 79.60 |
| Beta | 0.99 |
| Rel Volume | 0.50 |
| Avg Volume | 626.49K |
| Volume | 79,733 |
Performance
| Perf Week | 28.21% |
|---|---|
| Perf Month | 44.69% |
| Perf Quarter | 30.92% |
| Perf Half Y | 77.56% |
| Perf YTD | 61.93% |
| Perf Year | 42.05% |
| Perf 3Y | 71.96% |
| Perf 5Y | 36.94% |
| Perf 10Y | 2491.56% |
| Recom | 1.25 |
| Target Price | 65.43 |
| Prev Close | 59.03 |
| Price | 58.31 |
| Change % | -1.22% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Sep 17, 2025 | Downgrade | BBTIG Research | Buy → Neutral | ||
| Aug 09, 2024 | Initiated | CCanaccord Genuity | Buy | $57 | -2.2% |
| Jun 20, 2024 | Initiated | TTD Cowen | Buy | $55 | -5.7% |
| Jan 25, 2024 | Upgrade | TTruist | Hold → Buy | $39 → $51 | -12.5% |
| Aug 08, 2023 | Upgrade | BBTIG Research | Neutral → Buy | $39 | -33.1% |
| Nov 10, 2022 | Downgrade | BBTIG Research | Buy → Neutral | ||
| Nov 09, 2022 | Downgrade | TTruist | Buy → Hold | ||
| Oct 14, 2022 | Resumed | SStephens | Overweight | $40 | -31.4% |
| Jan 11, 2021 | Downgrade | OOppenheimer | Outperform → Perform | ||
| Dec 18, 2020 | Initiated | SStephens | Overweight | $31 | -46.8% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| MDXG | Mimedx Group Inc | 485.20M |
| RCEL | AVITA Medical Inc | 433.21M |
| ANIK | Anika Therapeutics Inc | 184.85M |
| IART | Integra Lifesciences Holdings Corp | 1.13B |
| MESO | Mesoblast Ltd ADR | 1.79B |
| SNN | Smith & Nephew plc ADR | 12.86B |
| CNMD | Conmed Corp | 1.52B |
| BVS | Bioventus Inc | 941.69M |
| ORGO | Organogenesis Holdings Inc | 124.95M |
| SYK | Stryker Corp | 120.54B |
Insider trading
latest 14 of 98| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| MCLAUGHLIN KEVIN F | Director | Nov 10 '26 | Proposed Sale | 58.39 | 7,000 | 408,730 | Nov 10 03:44 PM | |
| ZERBE ROBERT L MD | Director | Nov 09 '26 | Proposed Sale | 57.88 | 2,000 | 115,753 | Nov 09 04:29 PM | |
| Mara Joseph Anthony Jr | Officer | Nov 09 '26 | Proposed Sale | 58.26 | 25,000 | 1,456,544 | Nov 09 04:16 PM | |
| Mara Joseph Anthony Jr | Chief Financial Officer | Nov 06 '26 | Option Exercise | 32.32 | 28,641 | 925,540 | 30,759 | Nov 09 04:05 PM |
| Mara Joseph Anthony Jr | Chief Financial Officer | Nov 05 '26 | Option Exercise | 32.42 | 21,359 | 692,460 | 27,118 | Nov 09 04:05 PM |
| Mara Joseph Anthony Jr | Chief Financial Officer | Nov 06 '26 | Sale | 53.42 | 28,641 | 1,530,007 | 16,186 | Nov 09 04:05 PM |
| Mara Joseph Anthony Jr | Chief Financial Officer | Nov 05 '26 | Sale | 53.56 | 21,359 | 1,144,012 | 16,186 | Nov 09 04:05 PM |
| Mara Joseph Anthony Jr | Officer | Nov 06 '26 | Proposed Sale | 53.42 | 28,641 | 1,529,938 | Nov 06 04:21 PM | |
| SIEGAL JONATHAN | Principal Accounting Officer | Nov 05 '26 | Option Exercise | 34.90 | 1,500 | 52,350 | 2,759 | Nov 06 04:05 PM |
| SIEGAL JONATHAN | Principal Accounting Officer | Nov 05 '26 | Sale | 52.90 | 1,500 | 79,350 | 1,259 | Nov 06 04:05 PM |
| Flynn Sean C. | Chief Legal Officer | Nov 05 '26 | Option Exercise | 16.25 | 15,000 | 243,750 | 16,990 | Nov 06 04:05 PM |
| Flynn Sean C. | Chief Legal Officer | Nov 05 '26 | Sale | 51.92 | 15,000 | 778,800 | 1,990 | Nov 06 04:05 PM |
| ZERBE ROBERT L MD | Director | Nov 05 '26 | Option Exercise | 13.05 | 3,000 | 39,150 | 35,495 | Nov 06 04:05 PM |
| ZERBE ROBERT L MD | Director | Nov 04 '26 | Option Exercise | 13.05 | 2,500 | 32,625 | 35,495 | Nov 06 04:05 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| IJR | iShares Core S&P Small-Cap ETF | AUM: 106.27B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.38B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.50B |
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 687.42B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.06B |
| SPSM | State Street SPDR Portfolio S&P 600TM Small Cap ETF | AUM: 16.06B |
| IJT | iShares S&P Small-Cap 600 Growth ETF | AUM: 7.45B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.47B |
| IBB | iShares Biotechnology ETF | AUM: 11.36B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | - |
News
latest 14 of 206- Vericel Delivers Its Strongest Beat-And-Raise Of 2026, But Burn Care Spike And A Cautious 2027 Signal Temper The Story (Earnings Whispers) +13.85%
- Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance (GlobeNewswire)
- Vericel Must Prove Its Second-Half Macy Slowdown Is Caution, Not Reality (Earnings Whispers) -5.04%
- Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire)
- Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) (FinanceWire)
- Loading…
- Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026 (GlobeNewswire)
- Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison (IPO-Edge.com)
- Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program (GlobeNewswire)
- Why is Cathie Wood's ARK Fund Backing this Israeli Innovator? (NASDAQ: MDWD) (FinanceWire)
- Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026 (GlobeNewswire)
- Three Years of War Changed What Governments Buy. One Player is Already Winning Contracts (NASDAQ: MDWD) (FinanceWire)
- Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026 (GlobeNewswire)
- Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance (GlobeNewswire)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-11-05 | 0.270 | 0.057 | 0.270 | 85.37 | 77.99 | 8 |
| 2026Q2 | 2026-07-30 | 0.040 | -0.029 | 0.042 | 77.46 | 72.70 | 8 |
| 2026Q1 | 2026-05-07 | -0.120 | -0.153 | -0.124 | 68.43 | 63.68 | 8 |
| 2025Q4 | 2026-02-26 | 0.450 | 0.391 | 0.446 | 92.92 | 90.97 | 8 |
| 2025Q3 | 2025-11-06 | 0.100 | -0.006 | 0.098 | 67.50 | 64.56 | 8 |
| 2025Q2 | 2025-07-31 | -0.010 | -0.032 | -0.011 | 63.24 | 64.48 | 8 |
| 2025Q1 | 2025-05-08 | -0.230 | -0.124 | -0.225 | 52.60 | 53.80 | 8 |
| 2024Q4 | 2025-02-27 | 0.380 | 0.320 | 0.379 | 75.38 | 76.51 | 8 |
| 2024Q3 | 2024-11-07 | -0.020 | -0.048 | -0.018 | 57.91 | 55.21 | 7 |
| 2024Q2 | 2024-08-01 | -0.100 | -0.093 | -0.096 | 52.66 | 52.59 | 7 |
| 2024Q1 | 2024-05-08 | -0.080 | -0.110 | -0.080 | 51.28 | 49.07 | 6 |
| 2023Q4 | 2024-02-29 | 0.260 | 0.174 | 0.257 | 65.00 | 63.95 | 5 |
| 2023Q3 | 2023-11-08 | -0.080 | -0.121 | -0.077 | 45.58 | 45.14 | 6 |
| 2023Q2 | 2023-08-02 | -0.110 | -0.152 | -0.106 | 45.92 | 42.14 | 5 |
| 2023Q1 | 2023-05-10 | -0.160 | -0.153 | -0.158 | 41.02 | 37.88 | 5 |
| 2022Q4 | 2023-02-23 | 0.120 | 0.036 | 0.120 | 52.69 | 52.88 | 5 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2019FY | -0.220 | -0.232 | -0.219 | 117.85 | 117.45 |
| 2020FY | 0.060 | 0.007 | 0.061 | 124.18 | 123.94 |
| 2021FY | -0.160 | -0.112 | -0.161 | 156.18 | 157.58 |
| 2022FY | -0.350 | -0.444 | -0.355 | 164.37 | 164.57 |
| 2023FY | -0.070 | -0.160 | -0.067 | 197.52 | 196.46 |
| 2024FY | 0.200 | 0.136 | 0.201 | 237.22 | 238.38 |
| 2025FY | 0.320 | 0.266 | 0.320 | 276.26 | 274.37 |
| 2026FY | - | 0.759 | - | - | 345.33 |
| 2027FY | - | 0.945 | - | - | 398.36 |
| 2028FY | - | 1.394 | - | - | 459.67 |
| 2029FY | - | 1.870 | - | - | 536.31 |
| 2030FY | - | 2.800 | - | - | 666.11 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q4 | S | 2026-11-09 | 8 | 7 | 0 | 113.99 | 113.17 | 114.6 |
| 2026Q4 | S | 2026-11-05 | 8 | 6 | 0 | 113.76 | 112.12 | 114.6 |
| 2026Q4 | S | 2026-11-03 | 8 | 0 | 0 | 112.37 | 111.13 | 115.6 |
| 2026Q4 | S | 2026-10-14 | 8 | 0 | 0 | 112.37 | 111.13 | 115.6 |
| 2026Q4 | S | 2026-10-13 | 8 | 0 | 1 | 112.37 | 111.13 | 115.6 |
| 2026Q4 | S | 2026-10-09 | 8 | 2 | 1 | 112.37 | 111.13 | 115.6 |
| 2026Q4 | S | 2026-08-20 | 8 | 2 | 1 | 112.37 | 111.13 | 115.6 |
| 2026Q4 | S | 2026-08-19 | 8 | 2 | 1 | 112.36 | 111.13 | 115.6 |
| 2026Q4 | S | 2026-08-18 | 8 | 2 | 1 | 112.36 | 111.13 | 115.6 |
| 2026Q4 | S | 2026-07-31 | 8 | 2 | 1 | 112.4 | 111.13 | 115.6 |
| 2026Q4 | S | 2026-07-30 | 8 | 2 | 0 | 112.57 | 111.13 | 115.6 |
| 2026Q4 | S | 2026-07-21 | 8 | 0 | 0 | 111.63 | 106.86 | 114.1 |
| 2026Q4 | S | 2026-07-10 | 8 | 7 | 0 | 111.63 | 106.86 | 114.1 |
| 2026Q4 | S | 2026-07-09 | 8 | 7 | 0 | 111.63 | 106.86 | 114.1 |
Estimate history
| EPS, annual | -0.52 | -0.202 | -0.219 | 0.061 | -0.161 | -0.355 | -0.067 | 0.201 | 0.317 | 0.6318 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | -0.018 | 0.379 | -0.225 | -0.011 | 0.098 | 0.446 | -0.124 | 0.042 | 0.267 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
| Sales, annual | 63.924 | 90.857 | 117.85 | 124.179 | 156.184 | 164.365 | 197.516 | 237.224 | 276.259 | 324.17 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 57.905 | 75.376 | 52.598 | 63.24 | 67.503 | 92.918 | 68.425 | 77.457 | 85.371 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
| Shares, annual | 35.861 | 43.578 | 44.864 | 45.804 | 46.88 | 47.253 | 47.829 | 49.628 | 50.62 | 51.044 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 49.265 | 49.628 | 50.252 | 50.441 | 50.55 | 50.62 | 51.01 | 51.171 | 51.044 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 324.17 | 276.26 | 237.22 | 197.52 | 164.37 | 156.18 | 124.18 | 117.85 | 90.86 |
| Cost of Goods Sold Incl. D&A | 82.77 | 70.66 | 65.12 | 61.94 | 54.58 | 50.16 | 39.95 | 37.57 | 32.16 |
| Gross Profit | 241.41 | 205.60 | 172.11 | 135.58 | 109.79 | 106.03 | 84.23 | 80.28 | 58.70 |
| Selling, General and Administrative Excl. Other | 214.44 | 194.56 | 167.59 | 142.04 | 126.85 | 113.88 | 81.86 | 91.53 | 62.61 |
| Research and Development | 29.73 | 27.56 | 24.80 | 21.04 | 19.94 | 16.29 | 13.02 | 30.39 | 13.60 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 26.97 | 11.04 | 4.52 | -6.46 | -17.06 | -7.85 | 2.37 | -11.25 | -3.91 |
| Interest Expense | 0.64 | 0.63 | 0.61 | 0.60 | 0.37 | 0.00 | 0.01 | 0.01 | 1.73 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.36 |
| Net Income Before Taxes | 34.17 | 17.38 | 10.51 | -2.37 | -15.99 | -7.58 | 3.04 | -9.66 | -8.14 |
| Income Taxes | 0.86 | 0.86 | 0.15 | 0.81 | 0.72 | -0.11 | 0.18 | 0.00 | 0.00 |
| Consolidated Net Income | 33.31 | 16.52 | 10.36 | -3.18 | -16.71 | -7.47 | 2.86 | -9.66 | -8.14 |
| Net Income From Continuing Operations | 33.31 | 16.52 | 10.36 | -3.18 | -16.71 | -7.47 | 2.86 | -9.66 | -8.14 |
| Net Income | 33.31 | 16.52 | 10.36 | -3.18 | -16.71 | -7.47 | 2.86 | -9.66 | -8.14 |
| EPS (Recurring) | 0.63 | 0.32 | 0.20 | -0.07 | -0.35 | -0.16 | 0.06 | -0.22 | -0.14 |
| EPS (Basic, Before Extraordinaries) | 0.66 | 0.33 | 0.21 | -0.07 | -0.35 | -0.16 | 0.06 | -0.22 | -0.20 |
| EPS (Diluted) | 0.63 | 0.32 | 0.20 | -0.07 | -0.35 | -0.16 | 0.06 | -0.22 | -0.20 |
| EBITDA | 40.65 | 22.59 | 10.02 | -1.83 | -8.86 | -0.47 | 9.20 | -6.72 | -2.48 |
| Non-Operating Income (Expense) | 7.84 | 6.96 | 6.61 | 4.70 | 1.44 | 0.28 | 0.68 | 1.59 | 0.87 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 34.85 | 30.63 | 28.83 | 25.54 | 29.37 | 25.06 | 10.11 | 13.18 | 7.22 |
| Price To Earnings Ratio | 93.43 | 93.43 | 878.56 | - | - | - | 724.88 | - | - |
| Price To Sales Ratio | 6.56 | 6.80 | 11.96 | 8.58 | 7.55 | 11.69 | 11.76 | 6.52 | 7.71 |
| Gross Margin | 74.47 | 74.42 | 72.55 | 68.64 | 66.80 | 67.88 | 67.83 | 68.12 | 64.60 |
| Operating Margin | 8.32 | 4.00 | 1.90 | -3.27 | -10.38 | -5.03 | 1.91 | -9.55 | -4.30 |
| Net Margin | 10.27 | 5.98 | 4.37 | -1.61 | -10.17 | -4.78 | 2.31 | -8.20 | -8.96 |
| Shares Outstanding | 51.04 | 50.62 | 49.63 | 47.83 | 47.25 | 46.88 | 45.80 | 44.86 | 43.58 |
| Market Capitalization | 3,012.29 | 3,012.29 | 2,710.27 | 1,699.47 | 1,243.85 | 1,839.84 | 1,402.84 | 777.69 | 754.24 |
Income statement, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 85.37 | 77.46 | 68.42 | 92.92 | 67.50 | 63.24 | 52.60 | 75.38 |
| Cost of Goods Sold Incl. D&A | 22.76 | 21.05 | 19.16 | 19.79 | 17.92 | 16.63 | 16.32 | 16.88 |
| Gross Profit | 62.61 | 56.40 | 49.27 | 73.13 | 49.59 | 46.61 | 36.27 | 58.50 |
| Selling, General and Administrative Excl. Other | 50.42 | 55.97 | 57.33 | 50.71 | 46.13 | 48.64 | 49.06 | 40.02 |
| Research and Development | 6.88 | 7.49 | 8.10 | 7.25 | 6.32 | 6.73 | 7.26 | 4.92 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 12.19 | 0.43 | -8.06 | 22.41 | 3.45 | -2.03 | -12.79 | 18.48 |
| Interest Expense | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.15 | 0.15 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | 14.16 | 2.21 | -6.30 | 24.10 | 5.07 | -0.55 | -11.25 | 19.95 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.86 | 0.00 | 0.00 | 0.00 | 0.15 |
| Consolidated Net Income | 14.16 | 2.21 | -6.30 | 23.24 | 5.07 | -0.55 | -11.25 | 19.81 |
| Net Income From Continuing Operations | 14.16 | 2.21 | -6.30 | 23.24 | 5.07 | -0.55 | -11.25 | 19.81 |
| Net Income | 14.16 | 2.21 | -6.30 | 23.24 | 5.07 | -0.55 | -11.25 | 19.81 |
| EPS (Recurring) | 0.27 | 0.04 | -0.12 | 0.45 | 0.10 | -0.01 | -0.23 | 0.38 |
| EPS (Basic, Before Extraordinaries) | 0.28 | 0.04 | -0.12 | 0.46 | 0.10 | -0.01 | -0.23 | 0.40 |
| EPS (Diluted) | 0.27 | 0.04 | -0.12 | 0.45 | 0.10 | -0.01 | -0.23 | 0.38 |
| EBITDA | 15.89 | 4.05 | -4.80 | 25.50 | 6.39 | 0.80 | -10.11 | 19.96 |
| Non-Operating Income (Expense) | 2.13 | 1.93 | 1.92 | 1.85 | 1.78 | 1.63 | 1.70 | 1.63 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 7.82 | 9.08 | 11.29 | 6.65 | 8.70 | 10.14 | 11.51 | 6.25 |
| Price To Earnings Ratio | 93.43 | 108.78 | 104.52 | 149.54 | 252.37 | 1,077.22 | 241.71 | 878.56 |
| Price To Sales Ratio | 6.56 | 7.60 | 5.59 | 6.79 | 6.31 | 8.60 | 9.33 | 12.08 |
| Gross Margin | 73.34 | 72.82 | 72.00 | 78.70 | 73.46 | 73.71 | 68.96 | 77.61 |
| Operating Margin | 14.27 | 0.56 | -11.79 | 24.12 | 5.11 | -3.21 | -24.32 | 24.52 |
| Net Margin | 16.59 | 2.85 | -9.21 | 25.01 | 7.52 | -0.87 | -21.38 | 26.28 |
| Shares Outstanding | 51.04 | 51.17 | 51.01 | 50.62 | 50.55 | 50.44 | 50.25 | 49.63 |
| Market Capitalization | 3,012.29 | 2,272.02 | 1,633.06 | 1,821.17 | 1,587.98 | 2,142.09 | 2,237.06 | 2,710.27 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 137.50 | 126.74 | 127.33 | 119.54 | 103.40 | 75.81 | 69.72 | 82.92 | 26.86 |
| Short Term Receivables | 84.63 | 61.38 | 58.36 | 46.54 | 37.44 | 34.50 | 32.17 | 23.45 | 18.27 |
| Inventories | 17.56 | 17.37 | 13.09 | 15.99 | 13.38 | 9.36 | 6.82 | 3.56 | 3.79 |
| Other Current Assets | 7.74 | 7.29 | 6.85 | 4.80 | 4.25 | 3.89 | 2.95 | 2.85 | 1.58 |
| Total Current Assets | 247.44 | 212.78 | 205.63 | 186.87 | 158.46 | 123.56 | 111.66 | 112.78 | 50.51 |
| Net Property, Plant & Equipment | 173.17 | 173.26 | 115.10 | 57.37 | 59.03 | 57.74 | 32.25 | 5.91 | 4.07 |
| Total Investments and Advances | 61.40 | 39.88 | 25.28 | 19.96 | 25.90 | 24.31 | 9.34 | 0.00 | 0.00 |
| Intangible Assets | 5.62 | 6.25 | 6.88 | 7.50 | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.34 | 0.56 | 0.77 | 1.30 | 0.32 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 487.97 | 432.72 | 353.66 | 273.00 | 243.71 | 205.61 | 153.24 | 118.69 | 54.58 |
| Short Term Debt Incl. Current Port. of LT Debt | 14.09 | 9.37 | 6.19 | 4.34 | 2.99 | 4.43 | 5.50 | 0.00 | 0.35 |
| Accounts Payable | 15.83 | 23.85 | 22.35 | 16.93 | 9.02 | 6.75 | 6.34 | 7.11 | 5.55 |
| Other Current Liabilities | 19.24 | 17.07 | 17.21 | 16.19 | 14.04 | 11.29 | 7.95 | 7.68 | 7.19 |
| Total Current Liabilities | 49.15 | 50.29 | 45.75 | 37.46 | 26.05 | 22.48 | 19.80 | 14.79 | 13.09 |
| Long Term Debt | 84.18 | 90.47 | 81.96 | 43.27 | 47.19 | 48.87 | 22.35 | 0.00 | 16.89 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.67 | 2.06 |
| Total Liabilities | 133.33 | 140.75 | 127.70 | 80.73 | 73.24 | 71.35 | 42.15 | 16.46 | 32.04 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 354.64 | 291.97 | 225.95 | 192.27 | 170.46 | 134.26 | 111.09 | 102.23 | 22.54 |
| Total Shareholders Equity | 354.64 | 291.97 | 225.95 | 192.27 | 170.46 | 134.26 | 111.09 | 102.23 | 22.54 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 354.64 | 291.97 | 225.95 | 192.27 | 170.46 | 134.26 | 111.09 | 102.23 | 22.54 |
| Total Liabilities & Stockholders Equity | 487.97 | 432.72 | 353.66 | 273.00 | 243.71 | 205.61 | 153.24 | 118.69 | 54.58 |
| Book Value Per Share | 7.01 | 5.88 | 4.72 | 4.07 | 3.64 | 2.93 | 2.48 | 2.35 | 0.63 |
| Tangible Book Value Per Share | 6.89 | 5.76 | 4.58 | 3.91 | 3.64 | 2.93 | 2.48 | 2.35 | 0.63 |
| Full-Time Employees | 398 | 357 | 314 | 305 | 281 | 273 | 241 | 216 | 205 |
| Price to Book Ratio | 7.84 | 10.51 | 8.31 | 6.99 | 10.81 | 10.54 | 7.03 | 7.42 | 11.35 |
| Return on Assets | 3.59 | 2.64 | -1.02 | -6.47 | -3.33 | 1.60 | -7.11 | -9.39 | -33.51 |
| Return on Equity | 5.11 | 4.00 | -1.52 | -9.21 | -4.90 | 2.33 | -9.06 | -13.04 | -73.17 |
| Return on Invested Capital | 3.76 | 2.71 | -1.03 | -7.09 | -3.43 | 1.56 | -7.24 | -7.96 | -43.84 |
| Quick Ratio | 4.68 | 3.89 | 4.21 | 4.56 | 5.57 | 5.08 | 5.30 | 7.38 | 3.57 |
| Current Ratio | 5.03 | 4.23 | 4.49 | 4.99 | 6.08 | 5.50 | 5.64 | 7.62 | 3.86 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | 33.31 | 16.52 | 10.36 | -3.18 | -16.71 | -7.47 | 2.86 | -9.66 | -8.14 |
| Depreciation | 13.60 | 11.54 | 5.50 | 4.63 | 8.20 | 7.39 | 6.83 | 4.53 | 1.43 |
| Other Funds (Non Cash) | 43.71 | 45.20 | 42.75 | 37.83 | 36.33 | 35.28 | 14.25 | 12.61 | 10.33 |
| Funds from Operations | 90.62 | 73.27 | 58.61 | 39.27 | 27.82 | 35.19 | 23.95 | 7.48 | 3.62 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -25.31 | -21.36 | -0.45 | -3.96 | -11.21 | -6.15 | -6.37 | -14.66 | -4.03 |
| Cash from Operating Activities | 65.31 | 51.91 | 58.16 | 35.31 | 16.61 | 29.04 | 17.57 | -7.18 | -0.41 |
| Capital Expenditures | -7.42 | -27.16 | -63.97 | -27.51 | -7.60 | -7.92 | -2.63 | -2.62 | -2.68 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | -18.70 | -16.77 | -15.06 | 24.38 | -28.61 | 4.41 | -14.53 | 13.23 | -64.35 |
| Purchase of Investments | -68.51 | -72.37 | -68.21 | -55.23 | -69.55 | -60.02 | -63.06 | -72.35 | -66.55 |
| Sale Or Maturity of Investments | 49.81 | 55.60 | 53.15 | 79.61 | 40.94 | 64.44 | 48.52 | 85.58 | 2.20 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -26.12 | -43.94 | -79.03 | -3.13 | -36.21 | -3.50 | -17.16 | 10.62 | -67.03 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -0.90 | 13.93 | 24.52 | 6.00 | 3.65 | 11.18 | 6.63 | 5.29 | 77.11 |
| Repurchase of Common Pref Stock | -8.55 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 7.64 | 13.93 | 24.52 | 6.00 | 3.65 | 11.18 | 6.63 | 5.29 | 77.11 |
| Proceedsfrom Stock Options | 13.93 | 13.93 | 24.52 | 6.00 | 3.65 | 11.18 | 0.00 | 0.00 | 74.39 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -18.24 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -18.24 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -18.24 |
| Net Financing Active Other Cash Flow | -5.20 | -6.86 | -5.46 | -2.38 | -1.53 | -2.01 | -0.19 | -0.03 | 0.00 |
| Other Financing Activities Uses | -5.20 | -6.86 | -5.46 | -2.38 | -1.53 | -2.01 | -0.19 | -0.03 | 0.00 |
| Cash from Financing Activities | -6.10 | 7.07 | 19.05 | 3.62 | 2.12 | 9.17 | 6.44 | 5.26 | 58.86 |
| Net Change in Cash | 33.09 | 15.04 | -1.82 | 35.80 | -17.47 | 34.71 | 6.85 | 8.69 | -8.58 |
| Free Cash Flow | 57.89 | 24.75 | -5.81 | 15.30 | 9.02 | 21.12 | 14.95 | -9.80 | -3.09 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow | 36.72 | 75.88 | - | 110.78 | 137.70 | 86.45 | 97.69 | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 170.27 | 162.46 | 145.34 | 137.50 | 135.38 | 116.88 |
| Short Term Receivables | 81.80 | 75.71 | 72.38 | 84.63 | 60.43 | 64.29 |
| Inventories | 17.06 | 18.38 | 18.35 | 17.56 | 18.16 | 16.83 |
| Other Current Assets | 11.65 | 8.18 | 7.99 | 7.74 | 8.01 | 6.58 |
| Total Current Assets | 280.77 | 264.73 | 244.06 | 247.44 | 221.97 | 204.58 |
| Net Property, Plant & Equipment | 165.67 | 167.62 | 170.52 | 173.17 | 175.47 | 177.25 |
| Total Investments and Advances | 65.34 | 64.97 | 65.28 | 61.40 | 49.66 | 47.40 |
| Intangible Assets | 5.16 | 5.31 | 5.47 | 5.62 | 5.78 | 5.94 |
| Other Assets | 0.18 | 0.23 | 0.29 | 0.34 | 0.40 | 0.45 |
| Total Assets | 517.11 | 502.87 | 485.63 | 487.97 | 453.27 | 435.61 |
| Short Term Debt Incl. Current Port. of LT Debt | 14.37 | 14.27 | 14.18 | 14.09 | 13.96 | 13.87 |
| Accounts Payable | 19.96 | 20.61 | 19.01 | 15.83 | 15.34 | 12.86 |
| Other Current Liabilities | 20.39 | 17.64 | 13.97 | 19.24 | 16.29 | 14.40 |
| Total Current Liabilities | 54.72 | 52.53 | 47.16 | 49.15 | 45.58 | 41.13 |
| Long Term Debt | 78.22 | 80.29 | 82.24 | 84.18 | 85.83 | 87.67 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 132.94 | 132.82 | 129.40 | 133.33 | 131.42 | 128.80 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 384.17 | 370.04 | 356.23 | 354.64 | 321.86 | 306.81 |
| Total Shareholders Equity | 384.17 | 370.04 | 356.23 | 354.64 | 321.86 | 306.81 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 384.17 | 370.04 | 356.23 | 354.64 | 321.86 | 306.81 |
| Total Liabilities & Stockholders Equity | 517.11 | 502.87 | 485.63 | 487.97 | 453.27 | 435.61 |
| Book Value Per Share | 7.53 | 7.23 | 6.98 | 7.01 | 6.37 | 6.08 |
| Tangible Book Value Per Share | 7.43 | 7.13 | 6.88 | 6.89 | 6.25 | 5.96 |
| Full-Time Employees | - | - | - | 398 | - | - |
| Price to Book Ratio | 7.84 | 6.37 | 4.59 | 5.66 | 5.17 | 7.24 |
| Return on Assets | 6.86 | 5.16 | 4.72 | 3.59 | 3.10 | 1.75 |
| Return on Equity | 9.44 | 7.16 | 6.59 | 5.11 | 4.52 | 2.59 |
| Return on Invested Capital | 3.06 | 0.49 | -1.44 | 5.30 | 1.24 | -0.14 |
| Quick Ratio | 4.82 | 4.69 | 4.79 | 4.68 | 4.47 | 4.56 |
| Current Ratio | 5.13 | 5.04 | 5.18 | 5.03 | 4.87 | 4.97 |
Cash flow, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Net Income | 14.16 | 2.21 | -6.30 | 23.24 | 5.07 | -0.55 |
| Depreciation | 3.63 | 3.62 | 3.27 | 3.09 | 2.94 | 2.83 |
| Other Funds (Non Cash) | 9.25 | 10.64 | 12.88 | 10.94 | 9.98 | 11.47 |
| Funds from Operations | 27.04 | 16.47 | 9.85 | 37.27 | 18.00 | 13.74 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -9.31 | -0.28 | 6.54 | -22.25 | 4.09 | -5.53 |
| Cash from Operating Activities | 17.72 | 16.19 | 16.38 | 15.01 | 22.08 | 8.21 |
| Capital Expenditures | -2.04 | -1.93 | -1.26 | -2.19 | -2.63 | -8.13 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -0.67 | -0.89 | -2.94 | -14.20 | -0.75 | -0.90 |
| Purchase of Investments | -10.62 | -11.85 | -17.19 | -28.85 | -14.54 | -15.54 |
| Sale Or Maturity of Investments | 9.95 | 10.96 | 14.25 | 14.65 | 13.80 | 14.65 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -2.71 | -2.82 | -4.20 | -16.39 | -3.38 | -9.03 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -6.58 | 2.86 | 1.56 | 1.25 | 1.48 | 1.79 |
| Repurchase of Common Pref Stock | -8.55 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 1.97 | 2.86 | 1.56 | 1.25 | 1.48 | 1.79 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 13.93 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.30 | -0.17 | -4.54 | -0.19 | -0.32 | -0.15 |
| Other Financing Activities Uses | -0.30 | -0.17 | -4.54 | -0.19 | -0.32 | -0.15 |
| Cash from Financing Activities | -6.88 | 2.69 | -2.98 | 1.06 | 1.17 | 1.64 |
| Net Change in Cash | 8.13 | 16.06 | 9.20 | -0.31 | 19.87 | 0.83 |
| Free Cash Flow | 15.68 | 14.26 | 15.13 | 12.83 | 19.45 | 0.08 |
| Price to Free Cash Flow | 36.72 | 37.74 | 34.40 | 75.77 | 80.17 | - |
Revenue breakdown
| Biopsy Kits | 2024: 2.10M 2025: 2.61M |
|---|---|
| Consolidation, Policy | 2024: 1.20M 2025: 2.08M |
| Epicel | 2024: 36.62M 2025: 32.07M |
| MACI Implants And Kits | 2024: 197.31M 2025: 239.51M |
| United States | 2024: 237.22M 2025: 276.26M |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 10.64% | 5.4M | 50.4M | 513.33K |
| 2026-10-15 | 10.35% | 5.2M | 50.6M | 508.81K |
| 2026-09-30 | 10.28% | 5.2M | 50.6M | 501.53K |
| 2026-09-15 | 10.84% | 5.5M | 50.6M | 562.09K |
| 2026-08-31 | 9.41% | 4.8M | 50.6M | 580.36K |
| 2026-08-14 | 9.34% | 4.7M | 50.6M | 581.62K |
| 2026-07-31 | 8.76% | 4.4M | 50.6M | 633.70K |
| 2026-07-15 | 9.12% | 4.6M | 50.5M | 644.87K |
| 2026-06-30 | 9.74% | 4.9M | 50.5M | 662.07K |
| 2026-06-15 | 10.49% | 5.3M | 50.4M | 659.65K |
| 2026-05-29 | 10.06% | 5.1M | 50.5M | 655.27K |
| 2026-05-15 | 10.58% | 5.3M | 50.5M | 648.72K |
| 2026-04-30 | 9.87% | 5.0M | 50.4M | 598.58K |
| 2026-04-15 | 10.09% | 5.1M | 50.3M | 577.23K |
| 2026-03-31 | 10.70% | 5.4M | 50.3M | 584.30K |
| 2026-03-13 | 10.04% | 5.0M | 50.2M | 519.43K |
| 2026-02-27 | 9.56% | 4.8M | 50.2M | 527.03K |
| 2026-02-13 | 9.59% | 4.8M | 50.0M | 543.78K |
| 2026-01-30 | 9.20% | 4.6M | 50.0M | 608.58K |
| 2026-01-15 | 8.68% | 4.3M | 50.0M | 619.69K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 20.00 | 36.10 | 41.00 | 0.00 | 6.493 | 0.00 | 0.00 | 0.946 | -0.334 | 0.010 |
| call | 22.50 | 33.60 | 38.50 | 0.00 | 5.859 | 0.00 | 0.00 | 0.939 | -0.332 | 0.011 |
| call | 25.00 | 31.10 | 36.00 | 0.00 | 5.303 | 0.00 | 0.00 | 0.932 | -0.328 | 0.012 |
| call | 30.00 | 26.10 | 31.00 | 0.00 | 4.358 | 0.00 | 0.00 | 0.916 | -0.318 | 0.014 |
| call | 35.00 | 21.10 | 26.00 | 0.00 | 3.567 | 0.00 | 0.00 | 0.896 | -0.304 | 0.017 |
| call | 40.00 | 16.10 | 21.00 | 0.00 | 2.896 | 0.00 | 0.00 | 0.871 | -0.285 | 0.019 |
| call | 45.00 | 11.10 | 16.00 | 12.44 | 2.273 | 27.00 | 0.00 | 0.837 | -0.260 | 0.023 |
| call | 50.00 | 6.10 | 11.00 | 3.50 | 1.690 | 22.00 | 0.00 | 0.785 | -0.226 | 0.027 |
| call | 55.00 | 2.50 | 6.30 | 4.25 | 1.204 | 23.00 | 0.00 | 0.654 | -0.263 | 0.034 |
| call | 60.00 | 0.05 | 2.40 | 1.75 | 0.823 | 6.00 | 0.00 | 0.465 | -0.194 | 0.037 |
| put | 20.00 | 0.00 | 5.00 | 0.00 | 5.813 | 0.00 | 0.00 | -0.050 | -0.308 | 0.010 |
| put | 22.50 | 0.00 | 5.00 | 0.00 | 5.216 | 0.00 | 0.00 | -0.058 | -0.306 | 0.011 |
| put | 25.00 | 0.00 | 5.00 | 0.00 | 4.717 | 0.00 | 0.00 | -0.065 | -0.302 | 0.012 |
| put | 30.00 | 0.00 | 5.00 | 0.00 | 3.864 | 0.00 | 0.00 | -0.080 | -0.292 | 0.014 |
| put | 35.00 | 0.00 | 4.70 | 0.65 | 3.268 | 1.00 | 0.00 | -0.104 | -0.300 | 0.017 |
| put | 40.00 | 0.00 | 5.00 | 0.00 | 2.519 | 0.00 | 0.00 | -0.123 | -0.260 | 0.019 |
| put | 45.00 | 0.00 | 5.00 | 6.00 | 1.952 | 1.00 | 0.00 | -0.156 | -0.236 | 0.022 |
| put | 50.00 | 0.00 | 1.90 | 10.20 | 1.495 | 2.00 | 0.00 | -0.215 | -0.221 | 0.027 |
| put | 55.00 | 0.05 | 3.50 | 0.65 | 1.429 | 1.00 | 0.00 | -0.346 | -0.257 | 0.034 |
| put | 60.00 | 0.50 | 5.00 | 0.00 | 1.144 | 0.00 | 0.00 | -0.535 | -0.187 | 0.037 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-05 | SEC |
| 2026-11-06 | 144/A | SEC | ||
| 2026-11-06 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-05 | SEC |
| 2026-11-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-05 | SEC |
| 2026-11-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-04 | SEC |
| 2026-11-05 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-05 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-05 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-05 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-05 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-05 | 8-K | Current report | 2026-11-05 | SEC |
| 2026-11-04 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-14 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-12 | SEC |
| 2026-08-13 | SCHEDULE 13G/A | SEC | ||
| 2026-08-12 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-03 | SEC |
| 2026-08-03 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-31 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-30 | SEC |
| 2026-07-30 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-30 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-07-30 | 8-K | Current report | 2026-07-30 | SEC |
| 2026-06-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-26 | SEC |
| 2026-06-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-26 | SEC |
| 2026-06-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-26 | SEC |
| 2026-06-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-26 | SEC |
| 2026-06-26 | 144 | Filing for proposed sale of securities under Rule 144. | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 3.80M | 6 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 780.11K | 2 |
| 2026-07 | 0 | 0 | 220.05K | 1 |
| 2026-06 | 0 | 0 | 2.64M | 7 |
| 2026-05 | 0 | 0 | 947.75K | 5 |
| 2026-04 | 0 | 0 | 121.52K | 1 |
| 2026-03 | 0 | 0 | 1.60M | 3 |
| 2026-02 | 0 | 0 | 242.62K | 1 |
| 2026-01 | 0 | 0 | 404.80K | 1 |
| 2025-12 | 0 | 0 | 254.16K | 3 |
| 2025-11 | 0 | 0 | 674.67K | 3 |
Institutional holders
| Manager | % owned |
|---|---|
| BlackRock, Inc. | 15.85% |
| STATE STREET CORP | 6.45% |
| CONGRESS ASSET MANAGEMENT CO | 4.98% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.42% |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 3.83% |
| BNP Paribas Asset Management Holding S.A. | 3.21% |
| Conestoga Capital Advisors, LLC | 3.07% |
| GW&K Investment Management, LLC | 3.00% |
| Soleus Capital Management, L.P. | 2.86% |
| GEODE CAPITAL MANAGEMENT, LLC | 2.74% |
Funds
| Fund | % owned |
|---|---|
| iShares Core S&P Small-Cap ETF | 6.03% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 3.17% |
| iShares Russell 2000 ETF | 2.62% |
| CONESTOGA SMALL CAP FUND | 2.56% |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2.34% |
| Congress Small Cap Growth Fund | 2.13% |
| Loomis Sayles Small Cap Growth Fund | 1.27% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.14% |
| Fidelity Small Cap Index Fund | 1.10% |
| iShares Russell 2000 Growth ETF | 0.93% |
OakChart. VCEL. Cached 15 minutes.